Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

• ClinicalTrials.gov Identifier: NCT02649361
• Recruitment Status: Completed
• First Posted: January 7, 2016
• Last Update Posted: June 5, 2019
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Information provided by (Responsible Party): Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Tracking Information

• First Submitted Date: January 6, 2016
• First Posted Date: January 7, 2016
• Last Update Posted Date: June 5, 2019
• Study Start Date: January 2016
• Actual Primary Completion Date: July 23, 2018 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: January 6, 2016): Progress free survival (PFS) [ Time Frame: From randomization，each 42 days up to PD or death(up to 24 months) ]
• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: January 6, 2016)

• Overall Survival (OS) [ Time Frame: From randomization until death (up to 24 months) ]
• Objective Response Rate (ORR) [ Time Frame: each 42 days up to intolerance the toxicity or PD (up to 24 months) ]
• Disease Control Rate (DCR) [ Time Frame: each 42 days up to intolerance the toxicity or PD (up to 24 months) ]

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)
• Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Esophageal Squamous Cell Carcinoma(ALTER1102)
• Brief Summary: To compare the effects and safety of Anlotinib with placebo in patients with esophageal squamous cell carcinoma(ESCC).
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Esophageal Squamous Cell Carcinoma

Intervention

• Drug: Anlotinib
  Anlotinib p.o. qd
• Drug: Placebo
  Placebo p.o. qd

Study Arms

• Experimental: Anlotinib
  Anlotinib QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
  Intervention: Drug: Anlotinib
• Placebo Comparator: Placebo
  Placebo QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
  Intervention: Drug: Placebo

• Publications *: Huang J, Xiao J, Fang W, Lu P, Fan Q, Shu Y, Feng J, Zhang S, Ba Y, Zhao Y, Liu Y, Bai C, Bai Y, Tang Y, Song Y, He J. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial. Cancer Med. 2021 Mar;10(5):1681-1689. doi: 10.1002/cam4.3771. Epub 2021 Feb 14.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: June 4, 2019): 164
• Original Estimated Enrollment (submitted: January 6, 2016): 144
• Actual Study Completion Date: July 23, 2018
• Actual Primary Completion Date: July 23, 2018 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Histological documentation of esophageal squamous cell carcinoma；
• Advanced esophageal squamous cell carcinoma with distant metastasis(Stage IV),at least one measurable lesion (by RECIST1.1)
• Patients who at least have failed to a platinum-based chemotherapy treatment or chemotherapy containing paclitaxel.

Note: (1) Each line treatment refers to treatment duration at least one cycle using monotherapy or drug combination; (2)Adjuvant chemotherapy or neoadjuvant chemoradiation is permitted before the study (if disease recurred during adjuvant chemotherapy/neoadjuvant chemoradiation or recurred within 6 months after stopping treatment, adjuvant chemotherapy/neoadjuvant chemoradiation can be considered as first line systemic chemotherapy;

• 18-75 years,ECOG PS:0-2,Life expectancy of more than 3 months
• 4 weeks or more from the last cytotoxic therapy, radiation therapy or surgery
• Main organs function is normal
• Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped
• Patients should participate in the study voluntarily and sign informed consent

Exclusion Criteria:

• Patients whose primary lesion with active bleeding within 2 months
• Primary lesion not resected and has not shrinked after radiation therapy
• Patients who have been failure with anti-tumor angiogenesis drug treatment
• Patients with factors that could affect oral medication (such as dysphagia，chronic diarrhea, intestinal obstruction etc.)
• Brain metastases patients with symptoms or symptoms controlled < 3 months

• Patients with any severe and/or unable to control diseases，including：

  1. Blood pressure unable to be controlled ideally(systolic pressure≥150 mmHg，diastolic pressure≥100 mmHg);
  2. Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QT≥480ms) and patients with Grade 1 or higher congestive heart failure (NYHA Classification);
  3. Patients with active or unable to control serious infections;
  4. Patients with cirrhosis, decompensated liver disease, or active hepatitis;
  5. Patients with poorly controlled diabetes (fasting blood glucose(FBG)>10mmol/L)
  6. Urine protein ≥ ++，and 24-hour urinary protein excretion>1.0 g confirmed
• Patients with non-healing wounds or fractures
• Patients with any CTC AE Grade 1 or higher bleeding events occurred in the lungs or any CTC AE Grade 2 or higher bleeding events occurred within 4 weeks prior to assignment;Patients with any physical signs of bleeding diathesis or receiving thrombolysis and anticoagulation
• Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism
• Patients with drug abuse history and unable to get rid of or Patients with mental disorders
• Imaging showed tumors have involved important blood vessels or by investigators determine likely during the follow-up study and cause fatal hemorrhage
• Patients participated in other anticancer drug clinical trials within 4 weeks
• History of immunodeficiency
• Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 75 Years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: China

Administrative Information

• NCT Number: NCT02649361
• Other Study ID Numbers: ALTN-11-II
• Has Data Monitoring Committee: No
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: Undecided

• Current Responsible Party: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Original Responsible Party: Same as current
• Current Study Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Original Study Sponsor: Same as current
• Collaborators: Not Provided
• Investigators: Not Provided
• PRS Account: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Verification Date: June 2019